AOX3 Inhibitors are a specialized class of chemical compounds designed to specifically target and inhibit the activity of the AOX3 enzyme, a member of the aldehyde oxidase family. AOX3 is involved in the oxidation of aldehydes and heterocyclic compounds, playing a critical role in various metabolic pathways, including the detoxification of endogenous and exogenous aldehydes. The enzyme catalyzes the conversion of aldehydes into carboxylic acids through an oxidative process that involves the transfer of electrons, using molecular oxygen as the final electron acceptor. AOX3 Inhibitors function by binding to the active site of the enzyme, where they can either compete with the natural substrate or interfere with the enzyme's ability to facilitate electron transfer. This inhibition effectively blocks the enzyme's catalytic activity, disrupting the normal metabolic processes in which AOX3 is involved.
The chemical properties of AOX3 Inhibitors are crucial for their specificity and efficacy. These inhibitors are typically designed with a molecular structure that closely resembles the natural substrates of AOX3, allowing them to fit snugly into the enzyme's active site. This structural mimicry enables the inhibitors to compete effectively with the natural substrates, preventing them from binding and undergoing oxidation. In addition to substrate analogs, some AOX3 Inhibitors may include functional groups that can form covalent or non-covalent interactions with key residues in the active site, such as cysteine or histidine, which are involved in the enzyme's catalytic mechanism. These interactions can stabilize the inhibitor within the active site, enhancing its ability to block the enzyme's activity. The solubility, stability, and bioavailability of these inhibitors are optimized to ensure they can reach the AOX3 enzyme in its native environment and maintain effective inhibition over time. Furthermore, the kinetics of inhibitor binding, including the rates of association and dissociation, are critical factors that determine the potency and duration of inhibition. By studying the interactions between AOX3 Inhibitors and the enzyme, researchers can gain valuable insights into the role of AOX3 in metabolic pathways and the broader implications of inhibiting this enzyme in various biological processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vitamin K3 | 58-27-5 | sc-205990B sc-205990 sc-205990A sc-205990C sc-205990D | 5 g 10 g 25 g 100 g 500 g | $25.00 $35.00 $46.00 $133.00 $446.00 | 3 | |
Menadione inhibits aldehyde oxidase 3 by serving as a substrate analogue that competes with natural substrates, leading to the functional inhibition of enzyme activity. | ||||||
Raloxifene | 84449-90-1 | sc-476458 | 1 g | $802.00 | 3 | |
Raloxifene inhibits aldehyde oxidase 3 by binding to the enzyme's active site, thereby blocking access of the enzyme's natural substrates. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $28.00 $37.00 | 18 | |
Indomethacin binds to the molybdenum cofactor in aldehyde oxidase 3, inhibiting the enzymatic activity by disrupting the catalytic function of the enzyme. | ||||||
Thiabendazole | 148-79-8 | sc-204913 sc-204913A sc-204913B sc-204913C sc-204913D | 10 g 100 g 250 g 500 g 1 kg | $31.00 $82.00 $179.00 $306.00 $561.00 | 5 | |
Thiabendazole inhibits aldehyde oxidase 3 by binding to the enzyme's active site and interfering with substrate access, thereby decreasing its enzymatic function. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A | 50 mg 500 mg | $68.00 $357.00 | 11 | |
Clozapine inhibits aldehyde oxidase 3 by acting as a substrate that is poorly metabolized, thereby competitively inhibiting the oxidation of physiological substrates. | ||||||
Methimazole | 60-56-0 | sc-205747 sc-205747A | 10 g 25 g | $69.00 $110.00 | 4 | |
Methimazole inhibits aldehyde oxidase 3 by interacting with the molybdenum cofactor, essential for the enzyme's catalytic activity, thus leading to inhibition. | ||||||